When given to people at earlier stages of Parkinson’s disease, deep brain stimulation (DBS) reduces the complexity of their treatment, while safely providing long-term motor benefits and possibly slowing disease progression, data from a five-year pilot trial suggests. A planned Phase 3 study has already received the…
Ongentys (opicapone) has been approved in Japan as an oral, add-on daily treatment for Parkinson’s disease patients experiencing off periods while on a levodopa/carbidopa regimen. This decision adds Japan to the list of countries where Ongentys is available as an add-on treatment for Parkinson’s motor symptoms, including the U.S. and…
The University at Buffalo has received a $2.2 million grant from the National Institute of Neurological Disorders and Stroke to develop a new method for diagnosing Parkinson’s disease before the onset of clinical symptoms, according to a university press release. Called “Molecular Segregation of Parkinson’s Disease…
The four winners of the Michael J. Fox Foundation (MJFF) and Sage Bionetworks Parkinson’s disease (PD) challenge to create new ways of using everyday technology to benchmark and predict disease progression remotely — including at home — have been announced. Called the Biomarker and Endpoint Assessment…
The U.S. Food and Drug Administration (FDA) has approved the Percept PC Neurostimulator by Medtronic, designed to allow for a more individualized use of deep brain stimulation therapy in people with Parkinson’s disease and related disorders. While this device is the fourth deep brain stimulation (DBS) system to…
Alterations in the levels of melatonin — the hormone that controls sleep-wake cycles — circulating in the blood are associated with certain non-motor symptoms of Parkinson’s disease, namely sleep disturbances, gastrointestinal issues, and heart problems. The study with that finding, “Elevated Plasma Melatonin Levels…
Lower than usual activity in a complex that recycles proteins in cells — called the proteosome — leads to an age-related buildup of protein aggregates in the brains of fish, similar to that seen in neurodegenerative diseases such as Parkinson’s, a study reported. Low proteasome activity…
The Parkinson’s Foundation announced the three winners of this year’s Nurse Faculty Award, giving about $10,000 to each of these nurses to support projects that might better the lives of Parkinson’s patients in their communities. Each winner is a graduate of the organization’s 50-hour accredited Edmond J. Safra Visiting Nurse Faculty…
Seelos Therapeutics has begun a preclinical study in rodents to test a gene therapy approach to deliver its investigational candidate SLS-007, a potential treatment for Parkinson’s disease. Results are expected by late this year or early 2021. One hallmark of Parkinson’s disease progression is the formation of…
The Michael J. Fox Foundation (MJFF) is offering a guide to help people newly diagnosed with Parkinson’s navigate the early days of their disease, and better prepare for the future. Called “If I Knew Then What I Know Now: The Michael J. Fox Foundation Patient Council’s Guide for People…
Get regular updates to your inbox.
